BiotechTube

LXS196 + LXS196 and HDM201

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Uveal Melanoma

Conditions

Uveal Melanoma

Trial Timeline

Feb 1, 2016 → Jan 7, 2022

NCT ID
NCT02601378

About LXS196 + LXS196 and HDM201

LXS196 + LXS196 and HDM201 is a phase 1 stage product being developed by Novartis for Uveal Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02601378. Target conditions include Uveal Melanoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02601378Phase 1Terminated

Competing Products

20 competing products in Uveal Melanoma

See all competitors
ProductCompanyStageHype Score
Pembrolizumab + LenvatinibEisaiPhase 2
52
Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mgAstraZenecaPhase 1
33
Pembrolizumab + EntinostatMerckPhase 2
52
Pembrolizumab + OlaparibMerckPhase 2
52
Pembrolizumab 25 MG/1 ML Intravenous SolutionMerckPhase 2
52
AEB071NovartisPhase 1
33
DYP688NovartisPhase 1/2
41
RAD001 (Everolimus) and Pasireotide (SOM230) LARNovartisPhase 2
52
ranibizumab + triamcinolone acetonideNovartisPhase 2/3
65
CrizotinibPfizerPhase 2
51
Dacarbazine + SunitinibPfizerPhase 2
51
AEB071 + MEK162PfizerPhase 1/2
40
Binimetinib + BelinostatPfizerPhase 2
51
Ipilimumab + NivolumabBristol Myers SquibbPhase 1
32
Nivolumab + RelatlimabBristol Myers SquibbPhase 2
51
ipilimumab + NivolumabBristol Myers SquibbPhase 2
51
ZIV-Aflibercept + CemiplimabSanofiPhase 2
51
Ziv-AfliberceptRegeneron PharmaceuticalsPhase 2
51
XmAb®23104 + Yervoy® (ipilimumab)ICON plc.Phase 1
30
IDE196 + Binimetinib + CrizotinibIDEAYA BiosciencesPhase 1/2
36

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85